SCHEMBL25314681

SCHEMBL25314681

CCOC(=O)c1nnccc1Nc1cc(Cl)c(O)c(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TTR P02766 1/20 0.43
▸ DHODH Q02127 3/20 0.39
▸ ALDH1A1 P00352 3/20 0.39
▸ MAPT P10636 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ BRAF P15056 1/20 0.39
▸ EIF2AK3 Q9NZJ5 1/20 0.39
▸ ILK Q13418 1/20 0.39
▸ ATM Q13315 1/20 0.39
▸ BRD4 O60885 1/20 0.38
▸ METTL3 Q86U44 1/20 0.37
▸ GLP1R P43220 1/20 0.37
▸ CDC25B P30305 1/20 0.37
▸ KDM4E B2RXH2 2/20 0.36
▸ GAA P10253 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ CASP1 P29466 1/20 0.36
▸ ESR1 P03372 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25310116 0.82 KDM4E (0.42) TTRMAPTILKKDM4EGAA
SCHEMBL23486570 0.81 ILK (0.57) DHODHALDH1A1MAPTILKATM
SCHEMBL22609263 0.79 LMNA (0.50) ALDH1A1MAPTHTTILKBRD4
SCHEMBL25310291 0.74 TTR (0.40) TTRMAPT
SCHEMBL26631994 0.71 HTT (0.54) TTRDHODHMAPTHTTKDM4E
SCHEMBL15091224 0.71 SYK (0.69) ALDH1A1MAPTHTTILKATM
SCHEMBL23486571 0.70 ILK (0.56) DHODHALDH1A1MAPTILKATM
SCHEMBL353413 0.70 CYP1A2 (0.44) ALDH1A1MAPTHTTILKBRD4
SCHEMBL15109832 0.69 RAB9A (0.42) ALDH1A1MAPTHTTGAANPC1
SCHEMBL5767934 0.69 TSHR (0.52) ALDH1A1MAPTBRD4KDM4ECASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357134-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS UCL BUSINESS LTD (GB) 2023-11-09 — — US disclosed
US-20230357134-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS UCL BUSINESS LTD (GB) 2023-11-09 — — US disclosed
EP-4214189-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS UCL Business Ltd (GB) 2023-07-26 — — EP disclosed
WO-2022058733-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS UCL BUSINESS PLC (GB) 2022-03-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357134-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS TTR, C1R, APOB TTR 1/4885DHODH 3273/4885ALDH1A1 1891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback